{"id":575463,"date":"2021-11-17T19:12:01","date_gmt":"2021-11-17T19:12:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=575463"},"modified":"2021-11-17T19:12:01","modified_gmt":"2021-11-17T19:12:01","slug":"hypertrophic-cardiomyopathy-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hypertrophic-cardiomyopathy-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_575463.html","title":{"rendered":"Hypertrophic Cardiomyopathy Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"
\n
\"Hypertrophic<\/a><\/div>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s, \u201cHypertrophic Cardiomyopathy – Pipeline Insight, 2021,\u201d report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Hypertrophic Cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n

DelveInsight’s “Hypertrophic Cardiomyopathy Pipeline Insight”<\/a> <\/strong>report provides comprehensive insights about key companies and pipeline drugs in the Hypertrophic Cardiomyopathy pipeline landscapes. <\/p>\n

The report comprises Hypertrophic Cardiomyopathy pipeline<\/a><\/strong> drug profiles, including clinical and non-clinical stage products. It also includes the Hypertrophic Cardiomyopathy therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Hypertrophic Cardiomyopathy pipeline products.    <\/p>\n

\"\" <\/p>\n

Hypertrophic Cardiomyopathy Overview<\/strong><\/p>\n

Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). HCM occurs if heart muscle cells enlarge and cause the walls of the ventricles (usually the left ventricle) to thicken. The ventricle size often remains normal, but the thickening may block blood flow out of the ventricle. If this happens, the condition is called Obstructive hypertrophic cardiomyopathy (HOCN). Sometimes the septum, the wall that divides the left and right sides of the heart, thickens and bulges into the left ventricle. This can block blood flow out of the left ventricle. Then the ventricle must work hard to pump blood. Symptoms can include chest pain, dizziness, shortness of breath, or fainting.<\/p>\n

Some of the key takeaways from the Hypertrophic Cardiomyopathy Pipeline Report:<\/a><\/strong><\/p>\n